microenvironment. Our study suggests that instead of upregulating autophagy in an indirect manner, leukemic cells transfer autophagosomes to MSCs in order to enhance autophagy-induced cytokine secretion. In addition, our study identifies autophagosomes, ICAM1 and mitochondria as important structures that are actively transported from leukemic cells toward their microenvironment via TNTs.
To the editor:
Treatment of patients with chronic myeloid leukemia (CML) has changed dramatically over the years with the introduction of tyrosine kinase inhibitors (TKIs), now considered standard upfront therapy for this disease. Despite promising results, outcome of patients who present in advanced-phase or who progress while on TKI therapy is poor.
1,2 Allogeneic hematopoietic stem cell transplantation (AHSCT) remains the only potentially curative option for patients with advanced CML. ated transplant outcomes including the novel composite end point of graft-versus-host (GVHD)-free, relapse-free survival (GRFS). 4 In addition, in light of recent improvements with haploidentical (HAPLO) donors, we assessed transplant outcomes by donor type.
All consecutively treated patients with advanced CML, defined as beyond first chronic phase (CP1) who progressed to accelerated (AP) or blastic-phase (BP) treated from 01/2000 to 08/2015 at MD Anderson Cancer Center (MDACC) were included in this analysis. All patients provided written informed consent for transplant in accordance with the Declaration of Helsinki. The Institutional Review Board of MDACC approved the treatment protocols and this retrospective study.
Conditioning regimens varied; patients received either myeloablative (MAC) or reduced-intensity conditioning according to CIBMTR criteria. 5 GVHD prophylaxis for HLA-matched transplants consisted of tacrolimus and methotrexate of 5 mg/m 2 intravenously on day +1, +3, +6 and +11. Patients who received transplantation from HLA-matched unrelated or mismatched donors also received of anti-thymocyte globulin (15 mg/kg). GVHD prophylaxis regimen for HAPLO transplantation was with cyclophosphamide 50 mg/kg/ day on day +3, +4 (post-transplantation cyclophosphamide; PTCy), tacrolimus and mycophenolate mofetil.
Hematologic, cytogenetic and molecular responses pre-and post-transplant were defined according to the European LeukemiaNet response criteria. 6 The primary end point was progression-free survival (PFS). Secondary end points included GRFS (defined as the first event among acute GVHD (aGVHD) grades III-IV, extensive chronic GVHD (cGVHD), molecular relapse and death), 4 overall survival (OS), treatment-related mortality (TRM), relapse, aGVHD and cGVHD. Molecular relapse was defined as previously described. 7 The Kaplan-Meier method was used to estimate all survival measures. Differences in survival between groups were assessed using the log-rank test. Associations between post-transplant outcomes and patient subgroups of interest were determined using univariate Cox proportional hazards regression models (UVA). A multivariable Cox proportional hazards regression model (MVA) was used to determine the association between the post-transplant outcomes and those measures with P ⩽ 0.10 in the univariate assessments. The cumulative incidence (CI) function with the competing risks method was used to estimate the end points of relapse, TRM, aGVHD and cGVHD. Differences in CI between donor types were assessed using Gray's test. All statistical tests used a significance level of 5%.
Patient demographics and transplant characteristics are listed in Table 1 . Two hundred and seven consecutive advanced CML patients with median age of 44 years were evaluated in this study. Disease status at the time of transplant according to WHO criteria 8 was CP2, AP and BP in 160 (77%), 24 (12%) and 14 (7%) patients, respectively, and 9 (4%) patients had missing data. Donors were matched related (MRD), matched unrelated (MUD), HAPLO, mismatched unrelated (MMUD), umbilical cord blood (UCB) and 1 antigen mismatched related (MMRD) in 79 (38%), 75 (36%), 18 (9%), 17 (8%), 11 (5%) and 7 (3%) patients, respectively. There was no significant difference in demographic data of the patients in each donor type (Supplementary Table 1S ). The median time from diagnosis to transplant was 27 months (range 1.5-318 months). The median follow-up duration of patients who survived at last follow-up was 60 months.
The CI of aGVHD grades II-IV at 1 year post-transplant was 35%, whereas the CI of extensive cGVHD at 5 years was 31%. The CI of TRM at 1 year was 24%. There was no significant difference in the CI of severe aGVHD or cGVHD between donor types. The CI of cytogenetic and molecular relapse at 5 years post-transplant was 22 and 31%, respectively. For the entire group, the probability of PFS, OS and GRFS at 5 years was 49 and 22%, respectively. The median OS for patient in CP2, AP and BP were 97, 8 and 7 months, respectively. Follow-up duration of survivors (months), median (range) 60 (7.3-194) Abbreviations: ASCT, autologous stem cell transplantation; AP, accelerated phase; BP, blastic phase; CCgR, complete cytogenetic response; CP2, second chronic phase; HAPLO, haploidentical donor; MAC, myeloablative conditioning; MMolR, major molecular response; MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; UCB, umbilical cord blood donor; RIC, reduced intensity conditioning; TKIs, tyrosine kinase inhibitors.
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Adjusting for all significant factors, transplantation in CP2, using a HAPLO donor and MAC regimen were significantly associated with better PFS in MVA. The 5-year PFS of patients in CP2, AP and BP was 38, 23 and 14%, respectively (P = 0.007) (Figure 1a) . The 5-year PFS according to donor type was 59, 36, 34, 29, 14 and 18% in HAPLO, MRD, MUD, MMUD, MMRD and UCB group, respectively (P = 0.080) (Supplementary figure 1S) . Patients receiving a HAPLO donor had better 5-year PFS when compared with HLA MRD and MUD transplants, though not statistically significant (59 vs 35%, P = 0.11) (Figure 1b) .
For GRFS, transplant in CP2 and using HAPLO donor were significantly associated with better GRFS in MVA. The 5-year GRFS of patients in CP2, AP and BP before transplant was 24, 16 and 14%, respectively (P = 0.013) (Figure 1c) . The 5-year GRFS according to donor type was 53, 19, 23, 29, 0 and 9% in HAPLO, MRD, MUD, MMUD, MMRD and UCB group, respectively (P = 0.060) (Supplementary figure 1S) . Patients receiving a HAPLO donor had a better 5-year GRFS when compared with HLA-matched related and unrelated donor transplants (53 vs 21%, P = 0.019) (Figure 1d ).
AHSCT remains a standard approach for patients with advanced CML. 3, 9 The largest retrospective study from the Center for International Blood and Marrow Transplant Research (CIBMTR) showed a 3-year PFS of 37, 27 and 10% for patients in AP, CP2 and BP respectively. 3 Our results show a similar 5-year PFS for patients with advanced CML of 34% with a CI of cytogenetic and molecular relapse at 5 years of 22 and 31%, respectively.
To better appreciate the success of transplantation, we also analyzed a novel composite end point, GRFS, which reflects not only disease-free survival but also takes into consideration two major transplant complications, severe acute and chronic GVHD. Using this end point, 22% of patients survived to 5 years without experiencing a GRFS-defining event. This demonstrates that a large proportion of transplant survivors will be affected by significant GVHD-related complications. The use of PTCy, which has been shown to be associated with significantly lower incidence of severe acute and chronic GVHD in HAPLO transplants 10,11 may impact GRFS for HLA-matched transplants also; however, this remains to be determined.
The prognostic significance of disease phase pre-transplant has previously been established in several studies. 1, 9, 12 Transplantation in AP or BP has been shown to be associated with significantly worse outcomes, including by our group. 9, 12 Our study clearly showed that patients who returned to CP2 from AP or BP were more likely to achieve a post-transplant CCgR, and more than MMolR, which translated into a better survival when compared with patients transplanted in AP or BP.
In the absence of an HLA-matched donor, a HAPLO donor is the most accessible stem cell source as most patients will have a haplotype matched related donor in their immediate family. Due to effective GVHD prophylaxis using PTCy, outcomes of allografting with HAPLO donors have improved significantly with multiple retrospective studies now showing similar outcomes between HAPLO and HLA-matched transplants. 10, 11, [13] [14] [15] However, no study reported outcomes of patients treated with PTCy for patients with CML. We found that HAPLO transplantation performed with PTCy-based GVHD prophylaxis was associated with very low incidence of severe acute and chronic GVHD and better GRFS compared with other donor types. This might reflect not only the effectiveness of PTCy to control severe GVHD in this setting, but also a stronger GVT effect, since CML is one of the most sensitive hematological malignancies to a GVT effect. Although patients were not randomly selected into different donor groups and we had limited numbers of patients in each group, these results suggest that HAPLO transplantation with PTCy may be at least as effective as HLA-matched donor transplants performed with conventional GVHD prophylaxis for patients with advanced CML. Using a HAPLO donor could be considered if there is urgent need to proceed to transplant and a MUD is not immediately available. A prospective study with a sufficiently large number of HAPLO transplantations is needed to confirm the validity of the data.
In conclusion, our results indicate that, in addition to MAC and transplantation in CP2, AHSCT using HAPLO donors offers at least as good PFS and GRFS as HLA-matched transplants using conventional GVHD prophylaxis. Future studies will determine if this is largely a PTCy-based GVHD prophylaxis effect or outcomes are indeed improved with HAPLO transplants also because of a stronger GVT effect, which is known to occur in patients with CML.
